Research programme: anti-rabies monoclonal antibody - CelltrionAlternative Names: CT P19
Latest Information Update: 16 Mar 2016
At a glance
- Originator Celltrion
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rabies
Most Recent Events
- 16 Mar 2016 Preclinical development is ongoing in South Korea (Celltrion pipeline, March 2016)
- 18 Jul 2011 Preclinical development is ongoing in South Korea